[article] 
inJournal of Autism and Developmental Disorders > 52-10 (October 2022) . - p.4311-4320

Titre :	Autism: Comorbidities and Treatment Patterns in the Real World, a Retrospective Cohort Study Among Children, Adolescents and Adults Newly Diagnosed with Autism
Type de document :	Texte imprimé et/ou numérique
Auteurs :	Azza SHOAIB, Auteur ; M Soledad CEPEDA, Auteur ; Gayle MURRAY, Auteur ; Rachel OCHS-ROSS, Auteur
Article en page(s) :	p.4311-4320
Langues :	Anglais (eng)
Mots-clés :	Comorbid neurological conditions  Intervention patterns  Real world data  Treatment intervention  and development. AS and GM are employees and shareholders of Janssen research and  Development part of Johnson & Johnson.
Index. décimale :	PER Périodiques
Résumé :	We used real world data to summarize comorbidities and interventions among patients newly diagnosed with autism spectrum disorder (ASD). Data were derived from two claims-based US healthcare databases; Medicaid and Optum to construct a retrospective cohort of 36,000 patients. Attention-Deficit-Hyperactivity-Disorder (ADHD) was the most common co-morbidity (Medicaid: 50.09%; Optum: 44.16%), followed by mood disorder (Medicaid: 16.56% and Optum: 17.47%). Most patients received at least one type of treatment. Behavioral therapy was common (74.64% in Medicaid and 71.97% in Optum). More than half the cohorts received at least 1 pharmacotherapy. However, pharmacotherapies were diverse. Combination therapy and therapy switching was common. Understanding the clinical diversity and complexity of patients with ASD is an important first step in understanding unmet therapeutic needs.
En ligne :	http://dx.doi.org/10.1007/s10803-021-05289-x
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=486

[article] Autism: Comorbidities and Treatment Patterns in the Real World, a Retrospective Cohort Study Among Children, Adolescents and Adults Newly Diagnosed with Autism [Texte imprimé et/ou numérique] / Azza SHOAIB, Auteur ; M Soledad CEPEDA, Auteur ; Gayle MURRAY, Auteur ; Rachel OCHS-ROSS, Auteur . - p.4311-4320.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 52-10 (October 2022) . - p.4311-4320

Mots-clés :	Comorbid neurological conditions  Intervention patterns  Real world data  Treatment intervention  and development. AS and GM are employees and shareholders of Janssen research and  Development part of Johnson & Johnson.
Index. décimale :	PER Périodiques
Résumé :	We used real world data to summarize comorbidities and interventions among patients newly diagnosed with autism spectrum disorder (ASD). Data were derived from two claims-based US healthcare databases; Medicaid and Optum to construct a retrospective cohort of 36,000 patients. Attention-Deficit-Hyperactivity-Disorder (ADHD) was the most common co-morbidity (Medicaid: 50.09%; Optum: 44.16%), followed by mood disorder (Medicaid: 16.56% and Optum: 17.47%). Most patients received at least one type of treatment. Behavioral therapy was common (74.64% in Medicaid and 71.97% in Optum). More than half the cohorts received at least 1 pharmacotherapy. However, pharmacotherapies were diverse. Combination therapy and therapy switching was common. Understanding the clinical diversity and complexity of patients with ASD is an important first step in understanding unmet therapeutic needs.
En ligne :	http://dx.doi.org/10.1007/s10803-021-05289-x
Permalink :	https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=486